Loading...
Login/Register
Welcome
Profile
Log Off
text
title
chapter title
keyword
WHO Home
WHO Health Systems and Services
WHO Medicines
WHO sites
Medicines Documentation home
Search
Titles A-Z
Subjects
Keywords
Series and Periodicals
Publishers
Authors A-Z
Regions
Countries
Index
Sub-collections
Public
sub-collections
Expand Document
|
Expand Chapter
|
Full TOC
|
Printable HTML version
::
Themes & Keywords
·
Keywords
>
drug information
WHO Drug Information Vol. 17, No. 1, 2003
(2003; 77 pages)
Table of Contents
Reports on Individual Drugs
Women's Health Initiative Study
Menopausal combined hormone therapy update: Canada
Women's Health Initiative data review: USA
Future of hormone replacement therapy: Australia
Hormone replacement therapy recommendations: New Zealand
Vaccines and Biomedicines
Quality assurance and safety of biologicals
Production and quality control recommendations
Vaccines
Blood products
International Reference Materials
Current Topics
Direct-to-consumer drug advertising: survey results
Race and ethnicity data in clinical trials
HIV vaccine update
Drug bar code regulation proposed
Terminology in pharmacogenetics
New tool to boost access to quality medicines and detect counterfeits
Safety Issues
WHO Drug Dictionary: new structure - new focus
Tramadol - safety experience
Minocycline and intracranial hypertension
Neuropsychiatric events: celecoxib and rofecoxib
Linezolid: peripheral neuropathy
Zonisamide and visual hallucinations
Salmeterol study halted
Labelling and manufacturing of dietary supplements
Dietary supplements containing ephedra
Topical use of Lindane
Essential Medicines
Use of praziquantel in pregnant and lactating women
Benzimidazoles: use in children
Praziquantel 'dose pole' for large scale deworming
Poor access to praziquantel at the peripheral health care level
Regulatory and Safety Action
New class of HIV treatment approved
Influenza vaccine composition: Northern hemisphere
New labelling for conjugated estrogens
Fibrinolytics in diabetic patients
Precautions for blood and urine-derived products
Gefitinib: safety measures
Nefazodone: marketing suspended
Amifostine: serious reactions
Sirolimus: not recommended in lung transplant
Interferon beta-1a: strengthened labelling
Palivizumab: prescribing information changes
Epigallocatechin gallate marketing suspension
Pergolide mesilate: strengthened warning
Recent Publications and Sources of Information
WHO's new bookshop
WHO monographs on medicinal plants
International Pharmacopoeia: Volume 5
HIV treatment newsletter
Malaria: interactive self-assessment
Proposed International Nonproprietary Names: List 88
Annex 1 - PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES*
Annex 2 - GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES*
Annexe 1 - PROCEDURE A SUIVRE EN VUE DU CHOIX DE DENOMINATIONS COMMUNES INTERNATIONALES RECOMMANDEES POUR LES SUBSTANCES PHARMACEUTIQUES
Annexe 2 - DIRECTIVES GENERALES POUR LA FORMATION DE DENOMINATIONS COMMUNES INTERNATIONALES APPLICABLES AUX SUBSTANCES PHARMACEUTIQUES*
Anexo 1 - PROCEDIMIENTO DE SELECCION DE DENOMINACIONES COMUNES INTERNACIONALES RECOMENDADAS PARA LAS SUSTANCIAS FARMACEUTICAS
Anexo 2 - PRINCIPIOS GENERALES DE ORIENTACION PARA FORMAR DENOMINACIONES COMUNES INTERNACIONALES PARA SUSTANCIAS FARMACEUTICAS*
WHO Drug Information Vol. 17, No. 1, 2003
WHO Drug Information
is now available at:
http://www.who.int/druginformation
Contacts
|
E-mail scams
|
Employment
|
FAQs
|
Feedback
|
Privacy
|
RSS feeds
© WHO 2013
Last updated: May 3, 2013